Ipsen and Syntaxin partnered to discover and develop compounds to treat botulinum toxin

Syntaxin Ltd.

U.K. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Ipsen Group

France / Mid-Cap Biopharma ($1-$50 billion)

$2,709.4m on 10/21/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced